Transcriptomic Reprogramming Screen Identifies SRSF1 as a Regulator of Aging

Recent advances in cellular rejuvenation and longevity research have highlighted a critical limitation in conventional anti-aging methodologies: the dangerous compromise between reversing cellular age and preserving cellular identity. Historically, the foremost technique for cellular rejuvenation has relied upon the Yamanaka factors—Oct4, Sox2, Klf4, and c-Myc (OSKM)—which are capable of reprogramming fully differentiated somatic cells into induced pluripotent stem (iPS) cells. While this process successfully resets epigenetic clocks and erases biochemical markers of cellular senescence, it simultaneously strips the cell of its specialized identity, rendering it functionally naive and potentially oncogenic. This fundamental biological trade-off has forced researchers to look beyond pluripotency-inducing pathways in search of alternative mechanisms that can restore youthful vitality to aged tissues without inducing dedifferentiation.

Addressing this challenge, a collaborative research team spearheaded by scientists from Harvard Medical School and associated institutions has identified a novel molecular target with profound geroprotective potential. Published in the journal Nature Aging, the study reveals that SRSF1 (Serine/Arginine-Rich Splicing Factor 1), an essential RNA-processing and splicing protein, can profoundly rejuvenate human cells in vitro, extend lifespan, and significantly mitigate frailty in mammalian models. By leveraging an innovative machine-learning framework trained on transcriptomic data, the researchers successfully isolated a single factor capable of driving comprehensive cellular rejuvenation while strictly maintaining somatic cell identity, marking a monumental shift in therapeutic aging research.

The Chronology and Methodological Breakthrough of Transcriptomic Modeling

To navigate around the identity-loss pitfall associated with traditional partial reprogramming, the research team—including first co-author Dr. Alex Plesa and senior investigator Dr. George Church, a prominent Professor of Genetics at Harvard Medical School—decided to target the transcriptome rather than relying solely on stable epigenetic modifications. The rationale was rooted in the understanding that the transcriptome, representing the complete set of RNA transcripts expressed in a cell, dictates immediate cellular function and undergoes predictable, progressive shifts over the human lifespan.

The investigative process began with the construction of a robust transcriptomic aging model. Researchers trained a machine-learning predictor using extensive gene expression data derived from primary normal human dermal fibroblasts obtained from donors aged 1 to 96 years. Rather than evaluating individual genes in isolation, the algorithm was trained to assess cellular age by clustering gene expression data according to associated biological processes and functional modules.

Crucially, this machine-learning model demonstrated that gene expression profiles shift dynamically and exhibit far greater sensitivity to cellular age than the widely utilized DNA methylation (DNAm) clocks. While epigenetic clocks are invaluable for tracking chemical modifications to DNA over time, they are notoriously expensive, technically complex, and ill-suited for high-throughput pharmacological or genetic screening. In contrast, transcriptomic prediction provides a granular, highly responsive lens through which researchers can monitor how cells react to candidate anti-aging interventions in real time.

Utilizing this high-throughput transcriptomic age predictor, the team screened a curated library of preselected human genes previously implicated in aging-associated molecular networks. Each candidate gene was artificially overexpressed in human dermal fibroblasts to evaluate its systemic impact on the cellular transcriptome. Among the dozens of candidates tested, SRSF1 emerged as the most robust and consistent hit for driving transcriptomic rejuvenation, achieving restorative metrics comparable to the gold-standard OSKM factors without triggering the dangerous loss of cellular identity.

Cellular Rejuvenation Mechanics and Alternative Splicing Landscapes

Further in vitro analyses confirmed that the induction of SRSF1 successfully reverses a multitude of hallmark aging phenotypes in human dermal cells. Specifically, transient overexpression of SRSF1 led to a marked reduction in classical senescence markers, dampened the chronic inflammatory output associated with the senescence-associated secretory phenotype (SASP), alleviated endoplasmic reticulum and proteostatic stress, and simultaneously upregulated vital DNA repair pathways.

At the molecular level, the study illuminated how SRSF1 exerts these wide-ranging protective effects. As an RNA-processing and splicing factor, SRSF1 directly influences alternative splicing—a regulatory mechanism wherein exons are selectively included or excluded during pre-mRNA processing, allowing a single gene to encode multiple distinct protein isoforms. When SRSF1 was induced, it established a predictable, consistent alternative splicing landscape heavily dominated by alternative first exon usage (accounting for approximately 45% of events) and skipped exon events (accounting for approximately 25%).

When paired with differential gene expression analyses, these splicing patterns revealed a sophisticated dual regulation of critical pathways governing epigenetic maintenance and protein folding. Although the precise mechanistic cascade linking these alternative mRNA variants to whole-tissue rejuvenation requires further investigation, the data confirm that SRSF1 acts as a master regulator capable of re-tuning the cell’s functional output toward a more youthful state.

In Vivo Efficacy: Healthspan Extension and Frailty Reduction in Mammalian Models

Moving beyond cell culture models, the researchers evaluated the systemic, in vivo impacts of SRSF1 induction using aged murine models. Utilizing a viral vector tailored for liver tropism—meaning its expression was primarily targeted to hepatic tissue—the team induced SRSF1 expression in aging mice to observe whole-body physiological outcomes.

Despite the localized nature of the vector delivery, the systemic benefits observed were profound. Acute SRSF1 induction in aged mice yielded a striking 44% reduction in overall frailty burden, accelerated dermal wound healing capabilities, lowered overall mortality risk, and extended median lifespan by 14% compared to untreated control cohorts. These findings strongly support the hypothesis that targeted interventions in primary metabolic organs, such as the liver, can trigger systemic signaling cascades that communicate rejuvenation signals to distant tissues and organs throughout the body.

However, the in vivo experiments also underscored the critical importance of dosage regulation and treatment timing. When the researchers tested constitutive (constant, high-level) SRSF1 induction, the transgenic mice did not exhibit overt toxicity, but neither did they display improvements in muscle regeneration or wound repair. This dichotomy suggests that SRSF1 does not function as a blunt, perpetual "on switch" for cellular regeneration; rather, it requires precise, controlled dosing regimens to optimize its therapeutic window.

Expert Perspectives and Broader Implications for Longevity Therapeutics

The discovery of SRSF1’s geroprotective capabilities arrives at a pivotal juncture in modern biomedicine. As biotechnology advances at an exponential rate, the scientific community is increasingly shifting its focus from treating individual age-related pathologies—such as cardiovascular disease, neurodegeneration, and metabolic dysfunction—toward targeting the fundamental biological drivers of aging itself.

Reflecting on the study’s implications, Dr. Alex Plesa emphasized the delicate balance required in genetic engineering strategies. "In reprogramming, there is a fundamental tradeoff between rejuvenation and cell identity; achieving one without losing the other requires walking a fine line," Plesa noted. He further highlighted the scalability advantages of transcriptomic modeling: "The idea of predicting the age of cells based on their gene expression made a lot of sense, since every rejuvenation process inevitably has to manifest itself in altered gene expression programs that lead to the recovery of more youthful cell functionalities."

Dr. George Church elaborated on the long-term vision of translating these laboratory findings into clinical applications. "It has been a long-standing goal of my lab to devise clinically useful de-aging strategies by identifying genes that, when engineered in the genome for under or over-expression in aging target tissues, extend human healthspan," Church stated. "Our platform and findings on SRSF1 are an important step on that quest. Aging research is transiting an inflection point where the exponential progress of biotech is impacting the core aging processes which would otherwise kill 90% of us."

Future Outlook and Therapeutic Translation

While the preclinical data surrounding SRSF1 are exceptionally promising, researchers stress that significant hurdles remain before human clinical trials can be conceptualized. Future studies must focus on mapping the exact causal pathways linking SRSF1-driven alternative splicing events to systemic tissue repair, as well as developing advanced, non-viral or highly refined gene-delivery mechanisms capable of achieving precise, titratable expression in human target tissues.

Furthermore, additional toxicological and pharmacokinetic evaluations using larger, more diverse cohorts will be essential to confirm the safety and efficacy of modulating RNA-processing factors in living organisms. Should these subsequent investigations succeed, SRSF1 and its downstream signaling networks could pave the way for a new generation of targeted gene therapies designed to restore youthful vigor, compress morbidity, and significantly extend human healthspan without the catastrophic risks of cellular dedifferentiation.